These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

942 related articles for article (PubMed ID: 27445458)

  • 1. Secukinumab for rheumatology: development and its potential place in therapy.
    Koenders MI; van den Berg WB
    Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab: A Review in Psoriatic Arthritis.
    Shirley M; Scott LJ
    Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab (AIN457) in the treatment of ankylosing spondylitis.
    Braun J; Baraliakos X; Kiltz U
    Expert Opin Biol Ther; 2016; 16(5):711-22. PubMed ID: 26982813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab for the treatment of psoriatic arthritis.
    Baronaite Hansen R; Kavanaugh A
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Voulgari PV
    Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics in Inflammatory and Immunomediated Arthritis.
    Luchetti MM; Benfaremo D; Gabrielli A
    Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.
    Braun J; Kiltz U; Baraliakos X
    Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of IL-17 in the Human Immune System and Its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis.
    Jaller Char JJ; Jaller JA; Waibel JS; Bhanusali DG; Bhanusali N
    J Drugs Dermatol; 2018 May; 17(5):539-542. PubMed ID: 29742185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
    Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
    Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab: a promising therapeutic option in spondyloarthritis.
    Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
    Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
    Bagri NK; King H; Ramanan AV
    Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti cytokine therapy in chronic inflammatory arthritis.
    Thompson C; Davies R; Choy E
    Cytokine; 2016 Oct; 86():92-99. PubMed ID: 27497159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab for treating plaque psoriasis.
    Rothstein B; Gottlieb A
    Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
    Patel DD; Lee DM; Kolbinger F; Antoni C
    Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Iwaszko M; Wielińska J; Świerkot J; Kolossa K; Sokolik R; Bugaj B; Chaszczewska-Markowska M; Jeka S; Bogunia-Kubik K
    Front Immunol; 2021; 12():631603. PubMed ID: 34177886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of secukinumab in the treatment of ankylosing spondylitis.
    Shah R; Perry L; Deodhar A
    Immunotherapy; 2015; 7(12):1241-7. PubMed ID: 26595091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.